Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;28(8):2200390.
doi: 10.2807/1560-7917.ES.2023.28.8.2200390.

Epidemiology of Herpes Zoster in the pre-vaccination era: establishing the baseline for vaccination programme's impact in Spain

Carlos Risco Risco  1 , Zaida Herrador  2 , Noemí Lopez-Perea  2   3 , Diego Martínez-Urbistondo  1 , Rafael Suárez Del Villar Carrero  1 , Josefa Masa-Calles  2   3
Affiliations

Epidemiology of Herpes Zoster in the pre-vaccination era: establishing the baseline for vaccination programme's impact in Spain

Carlos Risco Risco et al. Euro Surveill. 2023 Feb.

Erratum in

  • Authors' correction for Euro Surveill. 2023;28(8).
    Eurosurveillance editorial team. Eurosurveillance editorial team. Euro Surveill. 2023 Mar;28(10):230309c1. doi: 10.2807/1560-7917.ES.2023.28.10.230309c1. Euro Surveill. 2023. PMID: 36892475 Free PMC article. No abstract available.

Abstract

BackgroundHerpes zoster (HZ) affects 1 in 3 persons in their lifetime, and the risk of HZ increases with increasing age and the presence of immunocompromising conditions. In Spain, vaccination guidelines were recently updated to include the recommendation of the new recombinant zoster vaccine (RZV) for certain risk groups.AimTo describe the epidemiology of HZ-related hospitalisations in Spain in order to prioritise vaccination recommendations and define a baseline to monitor the effectiveness of vaccination policies.MethodsRetrospective study using the National Health System's Hospital Discharge Records Database, including all HZ-related hospitalisations from 1998 to 2018.ResultsThe 65,401 HZ-related hospitalisations, corresponded to an annual mean hospitalisation rate of 6.75 per 100,000 population. There was an increasing trend of HZ hospitalisations over the study period. This rate was higher in males and older age groups, particularly over 65 years. Comorbidities with higher risk of readmission were leukaemia/lymphoma (RR 2.4; 95% CI: 2.3-2.6) and solid malignant neoplasm (RR 2.2; 95% CI: 2.1-2.4). Comorbidities associated with higher risk of mortality were leukaemia/lymphoma (RR 2.9; 95% CI: 2.7-3.2), solid malignant neoplasm (RR 2.9; 95% CI: 2.7-3.1) and HIV infection (RR 2.2; 95% CI: 1.8-2.7).ConclusionOf all patients hospitalised with HZ, those with greater risk of mortality or readmission belonged to the groups prioritised by the current vaccination recommendations of the Spanish Ministry of Health. Our study provided relevant information on clinical aspects of HZ and established the base for future assessments of vaccination policies.

Keywords: Epidemiology; Herpes Zoster; Herpes Zoster Vaccine; Spain.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Herpes zoster annual hospitalisation rates by sex and age group, Spain, 1998–2018 (n = 65,401)
Figure 2
Figure 2
Temporal trends of herpes zoster annual hospitalisation rates by age group, Spain, 1998–2018 (n = 65,401)
Figure 3
Figure 3
Herpes zoster mean hospitalisation per 100,000 inhabitants by autonomous community, Spain, 1998–2018 (n = 65,401)
See this image and copyright information in PMC

References

    1. Heyman D. Control of communicable diseases. Manual. 20th edition. American Public Health Association. Washington. 2015.
    1. Bricout H, Haugh M, Olatunde O, Prieto RG. Herpes zoster-associated mortality in Europe: a systematic review. BMC Public Health. 2015;15(1):466-466. 10.1186/s12889-015-1753-y - DOI - PMC - PubMed
    1. Nagel MA, Niemeyer CS, Bubak AN. Central nervous system infections produced by varicella zoster virus. Curr Opin Infect Dis. 2020;33(3):273-8. 10.1097/QCO.0000000000000647 - DOI - PubMed
    1. van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother. 2021;17(6):1714-32. 10.1080/21645515.2020.1847582 - DOI - PMC - PubMed
    1. Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81(10):928-30. 10.1212/WNL.0b013e3182a3516e - DOI - PMC - PubMed

Substances

LinkOut - more resources